Bispecific antibodies (bsAbs) have gained increasing interest in recent years because they can bind two antigens, offering unique modes of action compared to monoclonal antibodies. New and improved antibody bioprocesses and recombination techniques have contributed to a surge in the numbers of bispecific antibody constructs currently in clinical trials.
Alligator Bioscience AB develops antibody-based pharmaceuticals for cancer treatment, specializing in mono- and bispecific antibodies for tumor-directed immunotherapies. The company is active in the early stages of drug development, from early concepts to clinical phase II studies.
Explore an efficient downstream purification process for a cancer immunotherapy bispecific antibody (bsAb) that was developed in collaboration with Alligator Bioscience AB.